Matches in SemOpenAlex for { <https://semopenalex.org/work/W2413332885> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2413332885 endingPage "69" @default.
- W2413332885 startingPage "59" @default.
- W2413332885 abstract "23 patients with prostatic cancer were treated with (Estracyt) estramustine phosphate disodium, (Hexron) hexestrol, and (Honvah) diethylstilbestrol 4, 4-diphosphoric ester. 16 cases were given 560-840 mg of Estracyt, 6 cases 30 mg of Hexron, and 1 case 200 mg of Honvan orally daily. Fasting serum lipids and lipoproteins fractions were measured before and during this treatment with these drugs. The results were as follows. 1) In the 1-2 months of Estracyt administration a decrease of (TC) total cholesterol and extreme increase of (TG) triglycerides were confirmed. 2) In those 5 cases where 840 mg of Estracyt/day was given, almost no difference was observed in their TC, (NEFA) free fatty acids, or (PL) phospholipid values. 3) Cardiovascular complications although not serious, were found in 2 cases of the group receiving Estracyt. With these 2 cases, their beta+pre-beta/alpha lipoprotein fraction ratio decline was either very gradual or rather turned to increase markedly despite the extreme rise of their TG values. 4) The serum lipid values in the group receiving Hexron did not show any obvious changes in TG. These values did not change much in the first 5-6 months but an increase was seen between 7-9 months. Lipoprotein fractions were similar to those in the Estracyt group. 5) With those receiving Honvan, TG values began to rise 2-4 weeks following administration. In view of the above results, the coronary risk factors which are a consequence of Estracyt, Honvan, or Hexron ingestion for treatment of prostatic cancer must be taken very seriously and must be closely monitored. (Authors' modified)" @default.
- W2413332885 created "2016-06-24" @default.
- W2413332885 creator A5007906150 @default.
- W2413332885 creator A5030237364 @default.
- W2413332885 date "1980-01-01" @default.
- W2413332885 modified "2023-09-23" @default.
- W2413332885 title "[Clinical studies on serum lipids in the patients with tumor of the prostate gland. 2nd. Report. Changes of serum lipids and lipoprotein fractions during the treatment of estramustine phosphate disodium, hexestrol and diethylstilbestrol 4, 4-diphosphoric ester for the patients with prostatic cancer (author's transl)]." @default.
- W2413332885 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6155501" @default.
- W2413332885 hasPublicationYear "1980" @default.
- W2413332885 type Work @default.
- W2413332885 sameAs 2413332885 @default.
- W2413332885 citedByCount "0" @default.
- W2413332885 crossrefType "journal-article" @default.
- W2413332885 hasAuthorship W2413332885A5007906150 @default.
- W2413332885 hasAuthorship W2413332885A5030237364 @default.
- W2413332885 hasConcept C121608353 @default.
- W2413332885 hasConcept C126322002 @default.
- W2413332885 hasConcept C134018914 @default.
- W2413332885 hasConcept C139572402 @default.
- W2413332885 hasConcept C185592680 @default.
- W2413332885 hasConcept C2776235491 @default.
- W2413332885 hasConcept C2778163477 @default.
- W2413332885 hasConcept C2780072125 @default.
- W2413332885 hasConcept C2780201970 @default.
- W2413332885 hasConcept C2780890875 @default.
- W2413332885 hasConcept C2781397067 @default.
- W2413332885 hasConcept C2994223898 @default.
- W2413332885 hasConcept C71315377 @default.
- W2413332885 hasConcept C71924100 @default.
- W2413332885 hasConceptScore W2413332885C121608353 @default.
- W2413332885 hasConceptScore W2413332885C126322002 @default.
- W2413332885 hasConceptScore W2413332885C134018914 @default.
- W2413332885 hasConceptScore W2413332885C139572402 @default.
- W2413332885 hasConceptScore W2413332885C185592680 @default.
- W2413332885 hasConceptScore W2413332885C2776235491 @default.
- W2413332885 hasConceptScore W2413332885C2778163477 @default.
- W2413332885 hasConceptScore W2413332885C2780072125 @default.
- W2413332885 hasConceptScore W2413332885C2780201970 @default.
- W2413332885 hasConceptScore W2413332885C2780890875 @default.
- W2413332885 hasConceptScore W2413332885C2781397067 @default.
- W2413332885 hasConceptScore W2413332885C2994223898 @default.
- W2413332885 hasConceptScore W2413332885C71315377 @default.
- W2413332885 hasConceptScore W2413332885C71924100 @default.
- W2413332885 hasIssue "1" @default.
- W2413332885 hasLocation W24133328851 @default.
- W2413332885 hasOpenAccess W2413332885 @default.
- W2413332885 hasPrimaryLocation W24133328851 @default.
- W2413332885 hasRelatedWork W1972976281 @default.
- W2413332885 hasRelatedWork W1984261625 @default.
- W2413332885 hasRelatedWork W1996680438 @default.
- W2413332885 hasRelatedWork W2026528588 @default.
- W2413332885 hasRelatedWork W2036860907 @default.
- W2413332885 hasRelatedWork W2123662096 @default.
- W2413332885 hasRelatedWork W2154280507 @default.
- W2413332885 hasRelatedWork W2157219243 @default.
- W2413332885 hasRelatedWork W2410184831 @default.
- W2413332885 hasRelatedWork W91036948 @default.
- W2413332885 hasVolume "71" @default.
- W2413332885 isParatext "false" @default.
- W2413332885 isRetracted "false" @default.
- W2413332885 magId "2413332885" @default.
- W2413332885 workType "article" @default.